reports
Moleculin Biotech Inc: 1 director
A director at Moleculin Biotech Inc bought 109,955 shares at 0.981USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended D...
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018 HOUSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the year ended December 31, 2018. Additionally, the Company announced potential upcoming milestones and recent corporate developme...
Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Cl...
Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development HOUSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered into a sublicense agreement with WPD Pharmaceuticals (WPD), located in Poland. The agreement provides WPD with exclusive rights, ...
Moleculin Announces Approval for Third Drug to Commence Clinical Trial...
Moleculin Announces Approval for Third Drug to Commence Clinical Trials MBRX will now have three distinctive oncology drugs in clinic in four ongoing clinical trials WP1220, a STAT3 inhibitor, to begin clinical trials in Poland for the treatment of Cutaneous T-Cell Lymphona (“CTCL”), a rare and deadly skin cancer HOUSTON, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of...
Moleculin Announces the FDA has Granted Orphan Drug Designation for it...
Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug HOUSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate WP1066 for the treatment of glioblastoma, the most ...
Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology...
Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board Dr. Abbruzzese to add significant pancreatic cancer expertise to advance drug development HOUSTON, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that Dr. James L. Ab...
Moleculin Announces Patient Recruitment Begins in Annamycin Clinical T...
Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland Received European approval to ship Annamycin into Poland to start treating patients HOUSTON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has begun in Poland recruiting patients in the Company’s second clin...
Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candi...
Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate WP1732 now second lead drug demonstrating enhanced activity in combination with immune checkpoint blockade antibodies HOUSTON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that in preliminary animal studies, a second o...
REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakt...
REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018 HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a reminder it will host a conference call to discuss the recent discovery of a use of one of its molecules ...
Moleculin Announces Conference Call to Discuss FDA Filing and New Immu...
Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018 HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it will host a conference call to discuss the recent discovery of a use of one its molecule for cancer treatment and pro...
Moleculin Announces FDA Filing for Orphan Drug Designation for Gliobla...
Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has filed a request with the U.S. Food and Drug Administration (“FDA”) for Orphan Drug Status for its drug candidate WP1066. “Clinical progress with WP1066 ...
Moleculin Announces Breakthrough Discovery for its WP1066
Moleculin Announces Breakthrough Discovery for its WP1066 WP1066 shown to counteract resistance to checkpoint blockades HOUSTON, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that its own sponsored research has now confirmed a recent published study demonstrating the ability of its clinical-sta...
Moleculin Announces New Data Further Supporting Its Lead Drug for Trea...
Moleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer WP1732 shown to accumulate beneficially in pancreas HOUSTON, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that data from an independent test in animal models confirmed, as previously believed, that its...
Moleculin Requests FDA Meeting Regarding IND for New Cancer Drug
Moleculin Requests FDA Meeting Regarding IND for New Cancer Drug Testing confirms ability of WP1732 to target pancreatic cancer HOUSTON, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has filed a request with the US Food and Drug Administration (FDA) for a Pre-Investigational New Drug (IND) M...
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarte...
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018 HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the third quarter ended September 30, 2018. Additionally, the Company announced potential upcoming milestones and recent...
Moleculin Announces New Independent Study Expands Potential Use of Its...
Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122 Documented potential for drug candidate with characteristics like WP1122 to reverse immune suppression HOUSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that a new mechanism of action ma...
Moleculin Announces Significant Milestone Achieved in Glioblastoma Tri...
Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial WP1066 demonstrating drug bioavailability in on-going Phase 1 clinical trial HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced positive progress in the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor,...
Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials
Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials HOUSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that investigators at Emory University will present animal model data supporting the potential of WP1066 to treat pediatric brain tumors at the upcoming Society for Neuro-Onc...
Moleculin Announces New Data Discovery Confirming Significant Increase...
Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors Data to be Presented at Neuro-Oncology Annual Scientific Meeting HOUSTON, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that new data relating to its molecule WP1122 will be presented ...
Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Cli...
Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- In the ongoing challenge to combat the almost always deadly brain cancers, namely Glioblastoma and melanoma metastasized to the brain, the pharmaceutical company Moleculin Biotech, Inc., (Nasdaq: MBRX) has initiated a Phase 1 clinical trial of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.